Ojana Pharmaceutical Private Limited

Pharma franchise company manufacturing various medicines with 200+ clients and products.

2019 | Kaithal, Haryana (India) | Active
Last Updated:

Ojana Pharmaceutical Profile

Key Indicators

  • Authorised Capital ₹ 0.10 M
  • Paid Up Capital ₹ 0.10 M
  • Company Age 5 Year, 5 Months
  • Last Filing with ROC 31 Mar 2023
  • Revenue Growth 97.24%
  • Profit Growth -15.37%
  • Ebitda 2.17%
  • Net Worth 592.45%
  • Total Assets 51.97%

About Ojana Pharmaceutical

Ojana Pharmaceutical Private Limited (OPPL) is a Private Limited Indian Non-Government Company incorporated in India on 13 September 2019 (Five years and five months 22 days old ). Its registered office is in Kaithal, Haryana, India.

The Company is engaged in the Pharma Industry.

The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.

Sumit Mittal and Anjali Mittal serve as directors at the Company.

Company Details

  • Location

    Kaithal, Haryana, India

  • Telephone

    +91-XXXXXXXXXX

  • Email Address

  • Website

    ojanapharma.com

  • Social Media

Corporate Identity Details

  • CIN/LLPIN

    U24230HR2019PTC082559

  • Company No.

    082559

  • Company Classification

    Private Limited Indian Non-Government Company

  • Incorporation Date

    13 Sep 2019

  • Date of AGM

    30 Sep 2023

  • Date of Balance Sheet

    31 Mar 2023

  • Listing Status

    Unlisted

  • ROC Code

    Roc Delhi

Industry

Pharma

What products or services does Ojana Pharmaceutical Private Limited offer?

Ojana Pharmaceutical Private Limited offers a wide range of products and services, including Digestive System Drugs & Medicines, Gastrointestinal Drugs, Common Disease Medicines, Pharmaceutical Capsules, Pain Relief Drugs & Pharmaceuticals, Aceclofenac, Pharma & Bioanalytical Services, Pharmaceutical Third Party Manufacturing, Antihistamines, Anti Infective Drugs & Medicines.

Who are the key members and board of directors at Ojana Pharmaceutical?

Board Members (2)

NameDesignationAppointment DateStatus
Sumit Mittal Country flag representing In Director 13-Sep-2019Current
Anjali Mittal Country flag representing In Director 09-Mar-2022Current

Financial Performance of Ojana Pharmaceutical.

Ojana Pharmaceutical Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 97.24% increase. The company also saw a substantial fall in profitability, with a 15.37% decrease in profit. The company's net worth Soared by an impressive increase of 592.45%.

Ojana Pharmaceutical revenue growth over time
Ojana Pharmaceutical profit and loss trends over time
  • Key Matrics
  • Balance Sheet
  • Profit and Loss
  • Cash Flow
  • Ratios
Metrics
(FY 2023)YOY Growth
(FY 2022)(FY 2021)(FY 2020)(FY 2019)
Total Revenue
97.24%
Revenue from Operations
97.24%
Total Assets
51.97%
Profit or Loss
-15.37%
Net Worth
592.45%
EBITDA
2.17%

What is the Ownership and Shareholding Structure of Ojana Pharmaceutical?

Unlock access to Ojana Pharmaceutical's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.

Shareholding Indicator graph

Charges (Loans)

Placeholder for charges-related data

There are no open charges registered against the company as per our records.

How Many Employees Work at Ojana Pharmaceutical?

Unlock and access historical data on people associated with Ojana Pharmaceutical, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.

Employee growth trends for Ojana Pharmaceutical Private Limited

Deals i

Graph showing company valuation over time

Gain comprehensive insights into the Deals and Valuation data of Ojana Pharmaceutical, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Ojana Pharmaceutical's trajectory.

Rating

Graph displaying rating trends over time

Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.

Alerts

Alert Indicator

Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.

Latest Updates, News, and FAQs on Ojana Pharmaceutical

Recent activity within the organization

  • Annual General Meeting

    Ojana Pharmaceutical Private Limited last Annual general meeting of members was held on 30 Sep 2023 as per latest MCA records.

  • Balance Sheet

    Ojana Pharmaceutical Private Limited has filed its annual Financial statements for the year ended 31 Mar 2023 with Roc Delhi.

  • Director Appointment

    Anjali Mittal was appointed as a Director was appointed as a Director on 09 Mar 2022 & has been associated with this company since 2 years 11 months .

  • Director Appointment

    Sumit Mittal was appointed as a Director was appointed as a Director on 13 Sep 2019 & has been associated with this company since 5 years 5 months .

  • Company Incorporation

    Ojana Pharmaceutical Private Limited was registered on 13 Sep 2019 with Roc Delhi & aged 5 years 5 months as per MCA records.

Frequently asked questions

  • What is the Incorporation or founding date of Ojana Pharmaceutical Private Limited?

    Ojana Pharmaceutical Private Limited was incorporated on 13 Sep 2019.

  • What is authorized share capital and paid-up capital of Ojana Pharmaceutical Private Limited?

    The authorized share capital of Ojana Pharmaceutical Private Limited is ₹ 0.10 M and paid-up capital is ₹ 0.10 M.

  • Who are the current board members & directors of Ojana Pharmaceutical Private Limited?

    Currently 2 directors are associated with Ojana Pharmaceutical Private Limited.

    • Sumit Mittal
    • Anjali Mittal
  • What is the registered address of Ojana Pharmaceutical Private Limited?

    As per Ministry of Corporate Affairs (Mca), the registered address of Ojana Pharmaceutical Private Limited is 41/12, Gandhi Nagar Rishi India, Kaithal, Haryana, 136027.

  • What is the corporate identification number (CIN) and company number of Ojana Pharmaceutical Private Limited?

    The corporate identification number (CIN) of Ojana Pharmaceutical Private Limited is U24230HR2019PTC082559 and the company number is 082559 as per Ministry of Corporate Affairs (MCA).

  • What is the official website of Ojana Pharmaceutical Private Limited?

    The Official website of Ojana Pharmaceutical Private Limited is https://www.ojanapharma.com

  • What has been the recent revenue trend for Ojana Pharmaceutical Private Limited?

    According to the financial reports for the fiscal year 2023, the revenue trend for Ojana Pharmaceutical Private Limited has risen by 97.24%.

  • What change has been observed in the net worth of Ojana Pharmaceutical Private Limited, and by what percentage?

    The financial reports for the fiscal year 2023 indicates that The net worth of Ojana Pharmaceutical Private Limited has experienced an upsurge of 592.45%.

  • When was the last Balance Sheet of Ojana Pharmaceutical Private Limited filed with the ROC?

    The most recent Balance Sheet for Ojana Pharmaceutical Private Limited was filed with the ROC on 31 Mar 2023.

People also Viewed

Similar Companies Based on Drug Formulation & Development